FRANK E. THOMAS - 04 Oct 2022 Form 4 Insider Report for Orchard Therapeutics plc

Role
Title: President & Chief Operating Officer
Signature
/s/ Frank E. Thomas
Issuer symbol
N/A
Transactions as of
04 Oct 2022
Net transactions value
$0
Form type
4
Filing time
06 Oct 2022, 18:11:15 UTC
Previous filing
19 Sep 2022
Next filing
13 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -426,185 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 426,185 $2.44 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Award $0 +426,185 $0.000000 426,185 04 Oct 2022 Ordinary Shares 426,185 $0.5800 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -184,229 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 184,229 $9.06 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Award $0 +184,229 $0.000000 184,229 04 Oct 2022 Ordinary Shares 184,229 $0.5800 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -100,000 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 100,000 $12.54 Direct F1, F3, F4
transaction ORTX Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 04 Oct 2022 Ordinary Shares 100,000 $0.5800 Direct F1, F3, F4
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -200,000 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 200,000 $13.58 Direct F1, F3, F5
transaction ORTX Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 04 Oct 2022 Ordinary Shares 200,000 $0.5800 Direct F1, F3, F5
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -150,000 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 150,000 $7.05 Direct F1, F3, F6
transaction ORTX Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 04 Oct 2022 Ordinary Shares 150,000 $0.5800 Direct F1, F3, F6
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -310,000 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 310,000 $5.98 Direct F1, F3, F7
transaction ORTX Stock Option (Right to Buy) Award $0 +310,000 $0.000000 310,000 04 Oct 2022 Ordinary Shares 310,000 $0.5800 Direct F1, F3, F7
transaction ORTX Stock Option (Right to Buy) Disposed to Issuer $0 -27,731 -100% $0.000000* 0 04 Oct 2022 Ordinary Shares 27,731 $5.98 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Award $0 +27,731 $0.000000 27,731 04 Oct 2022 Ordinary Shares 27,731 $0.5800 Direct F1, F2, F3
transaction ORTX Stock Option (Right to Buy) Award $0 +457,811 $0.000000 457,811 04 Oct 2022 Ordinary Shares 457,811 $0.5800 Direct F3, F8
transaction ORTX Stock Option (Right to Buy) Award $0 +75,000 $0.000000 75,000 04 Oct 2022 Ordinary Shares 75,000 $0.5800 Direct F3, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2 The shares subject to this option are fully vested and exercisable as of the date hereof.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F4 The shares subject to this option vest in equal monthly installments over the four years after January 16, 2019.
F5 The shares subject to this option vest in equal monthly installments over the four years after January 2, 2020.
F6 The shares subject to this option vest in equal monthly installments over the four years after April 1, 2020.
F7 The shares subject to this option vest in equal monthly installments over the four years after February 1, 2021.
F8 The shares subject to this option vest in equal monthly installments over the three years after October 4, 2022.
F9 The shares subject to this option vest in equal monthly installments over the two years after July 1, 2024.

Remarks:

Title: President & Chief Operating Officer